Companies developing peroxisome proliferator-activated receptor (PPAR) agonists, like Avandia, are urged to conduct two-year carinogenicity evaluations.
英
美
- 研发过氧物酶增殖子活化的受体(PPAR)激动剂,类似文迪雅的公司,要求做两年的基因评价。